Amylyx Pharmaceuticals Valuation
| AMLX Etf | USD 2.03 0.03 1.50% |
Based on Macroaxis valuation methodology, the entity appears to be undervalued. Amylyx Pharmaceuticals shows a prevailing Real Value of $7.72 per share. The current price of the entity is $2.03. Our model approximates the value of Amylyx Pharmaceuticals from analyzing the entity fundamentals such as Current Valuation of (229.53 M), profit margin of 0.13 %, and Return On Equity of 0.13 as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Price Book 0.3138 | Enterprise Value -229.5 M | Enterprise Value Ebitda (5.79) | Price Sales 0.3625 | Forward PE 2.7739 |
Undervalued
Today
Please note that Amylyx Pharmaceuticals' price fluctuation is very risky at this time. Calculation of the real value of Amylyx Pharmaceuticals is based on 3 months time horizon. Increasing Amylyx Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Amylyx Pharmaceuticals is useful when determining the fair value of the Amylyx etf, which is usually determined by what a typical buyer is willing to pay for full or partial control of Amylyx Pharmaceuticals. Since Amylyx Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Amylyx Etf. However, Amylyx Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.03 | Real 7.72 | Target 47.6 | Hype 2.0 | Naive 0.41 |
The real value of Amylyx Etf, also known as its intrinsic value, is the underlying worth of Amylyx Pharmaceuticals ETF, which is reflected in its stock price. It is based on Amylyx Pharmaceuticals' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Amylyx Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Amylyx Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Amylyx Pharmaceuticals helps investors to forecast how Amylyx etf's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Amylyx Pharmaceuticals more accurately as focusing exclusively on Amylyx Pharmaceuticals' fundamentals will not take into account other important factors: Amylyx Pharmaceuticals Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Amylyx Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Amylyx Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Amylyx Pharmaceuticals competition to find correlations between indicators driving Amylyx Pharmaceuticals's intrinsic value. More Info.Amylyx Pharmaceuticals is rated below average in price to book as compared to similar ETFs. It is rated below average in price to sales as compared to similar ETFs fabricating about 1.16 of Price To Sales per Price To Book. Comparative valuation analysis is a catch-all model that can be used if you cannot value Amylyx Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Amylyx Pharmaceuticals' Etf. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Amylyx Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Amylyx Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Amylyx Pharmaceuticals and how it compares across the competition.
About Amylyx Pharmaceuticals Valuation
The etf valuation mechanism determines the current worth of Amylyx Pharmaceuticals on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Amylyx Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this etf, attempts to find the value of Amylyx Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Amylyx Pharmaceuticals's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Amylyx Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Amylyx Pharmaceuticals. We calculate exposure to Amylyx Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Amylyx Pharmaceuticals's related companies.Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange.
8 Steps to conduct Amylyx Pharmaceuticals' Valuation Analysis
ETF's valuation is the process of determining the worth of any etf in monetary terms. It estimates Amylyx Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of etf valuation is a single number representing a ETF's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Amylyx Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Amylyx Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Amylyx Pharmaceuticals' revenue streams: Identify Amylyx Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Amylyx Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Amylyx Pharmaceuticals' growth potential: Evaluate Amylyx Pharmaceuticals' management, business model, and growth potential.
- Determine Amylyx Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the ETF's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Amylyx Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Amylyx Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Amylyx Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 70 M | |
| Forward Price Earnings | 2.7739 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amylyx Pharmaceuticals. Also, note that the market value of any etf could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Amylyx Etf please use our How to Invest in Amylyx Pharmaceuticals guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
The market value of Amylyx Pharmaceuticals is measured differently than its book value, which is the value of Amylyx that is recorded on the company's balance sheet. Investors also form their own opinion of Amylyx Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Amylyx Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amylyx Pharmaceuticals' market value can be influenced by many factors that don't directly affect Amylyx Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amylyx Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amylyx Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amylyx Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.